Core Viewpoint - Rhythm Pharmaceuticals, Inc. is set to report its fourth quarter and full year 2025 financial results on February 26, 2026, and will provide a corporate update during a live conference call [1] Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases [4] - The company's lead product, IMCIVREE (setmelanotide), is an MC4R agonist approved by the FDA for treating obesity related to specific genetic conditions [4][5] - Setmelanotide is also authorized by the European Commission and the UK's MHRA for similar indications [4][6] Upcoming Events - A live conference call for financial results will take place on February 26, 2026, at 8 a.m. ET, with a recommendation for participants to join ten minutes early [2] - David Meeker, M.D., will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, at 11:10 a.m. ET [2] Webcast Information - Live webcasts of the financial results conference call and the fireside chat will be available on the Rhythm Pharmaceuticals website [3] - Archived webcasts will be accessible for 30 days following the events [3]

Core Viewpoint - Rhythm Pharmaceuticals, Inc. is actively participating in the Guggenheim Emerging Outlook: Biotech Summit 2026, highlighting its commitment to addressing rare neuroendocrine diseases through its lead asset, setmelanotide [1][2]. Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on transforming the lives of patients with rare neuroendocrine diseases [3]. - The company's lead product, IMCIVREE (setmelanotide), is an MC4R agonist approved by the FDA for reducing excess body weight and maintaining weight reduction in patients aged 2 years and older with specific genetic obesity conditions [3][4]. - Setmelanotide has also received authorization from the European Commission and the UK's Medicines & Healthcare Products Regulatory Agency for similar indications [3][5]. Product Indications - In the U.S., setmelanotide is indicated for patients with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or deficiencies in POMC, PCSK1, or LEPR [4]. - In the EU and UK, it is indicated for obesity treatment and hunger control associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1 and LEPR deficiencies [5]. Clinical Development - Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases and is also exploring investigational MC4R agonists, bivamelagon and RM-718, along with a preclinical suite of small molecules for congenital hyperinsulinism [3]. Safety Information - Common adverse reactions associated with setmelanotide include skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection [13]. - Serious hypersensitivity reactions, including anaphylaxis, have been reported, necessitating caution in patients with prior hypersensitivity to the drug [6][10].